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Abstract
Objectives—Contamination of workplace surfaces by antineoplastic drugs presents an exposure 
risk for healthcare workers. Traditional instrumental methods to detect contamination such as 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) are sensitive and accurate but 
expensive. Since immunochemical methods may be cheaper and faster than instrumental methods, 
we wanted to explore their use for routine drug residue detection for preventing worker exposure.
Methods—In this study we examined the feasibility of using fluorescence covalent microbead 
immunosorbent assay (FCMIA) for simultaneous detection and semi-quantitative measurement of 
three antineoplastic drugs (5-fluorouracil, paclitaxel, and doxorubicin). The concentration ranges 
for the assay were 0–1000 ng/ml for 5-fluorouracil, 0–100 ng/ml for paclitaxel, and 0–2 ng/ml for 
doxorubicin. The surface sampling technique involved wiping a loaded surface with a swab wetted 
with wash buffer, extracting the swab in storage/blocking buffer, and measuring drugs in the 
extract using FCMIA.
Results—There was no significant cross reactivity between these drugs at the ranges studied 
indicated by a lack of response in the assay to cross analytes. The limit of detection (LOD) for 5-
fluorouracil on the surface studied was 0.93 ng/cm2 with a limit of quantitation (LOQ) of 2.8 
ng/cm2, the LOD for paclitaxel was 0.57 ng/cm2 with an LOQ of 2.06 ng/cm2, and the LOD for 
doxorubicin was 0.0036 ng/cm2 with an LOQ of 0.013 ng/cm2.
Conclusion—The use of FCMIA with a simple sampling technique has potential for low cost 
simultaneous detection and semi-quantitative measurement of surface contamination from 
multiple antineoplastic drugs.
Keywords
Antineoplastic drugs (5-fluorouracil, paclitaxel, doxorubicin); surface analysis; multiplex 
measurement
Corresponding author: Jerome P Smith, Division of Applied Research and Technology, National Institute for Occupational Safety 
and Health, US Centers for Disease and Control Prevention, 4676 Columbia Parkway, Cincinnati, OH 45226, USA. jps3@cdc.gov. 
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute 
for Occupational Safety and Health. Mention of company or product names does not imply endorsement by the National Institute for 
Occupational Safety and Health.
HHS Public Access
Author manuscript
J Oncol Pharm Pract. Author manuscript; available in PMC 2016 February 01.
Published in final edited form as:














Many antineoplastic drugs have known carcinogenic, mutagenic, and adverse reproductive 
effects (1, 2). Currently, an estimated 8 million US health care workers are potentially 
exposed to antineoplastic drugs (3). A number of studies have documented workplace 
contamination by antineoplastic drugs and have resulted in the development of safer 
handling procedures (4, 5). NIOSH has developed an Alert where information concerning 
the effects of exposure are given, processes producing exposure are described, and 
procedures for lowering exposure are presented (1). However recent studies have shown that 
despite following recommended safe handling practices, workplace contamination with 
antineoplastic drugs in pharmacy and nursing areas continues to occur (4, 5). Commercial 
preparations used in administering drugs to patients have concentrations of 50 mg/ml for 5-
fluorouracil, 6 mg/ml for pactlitaxel, and 2 mg/ml for doxorubicin so spillage of a low 
volume of the preparations can result in significant levels of contamination.
Analytical techniques for measurement of surface contamination by antineoplastic drugs 
such as liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) (6) are 
sensitive, specific, and accurate but the initial equipment investment is expensive and a 
trained analyst is required to operate the instrument so these methods often cannot be used 
on a frequent basis.
A technique called fluorescence covalent microbead immunosorbent assay (FCMIA) for 
performing multiple immunochemical determinations simultaneously has been developed by 
Luminex Corporation (7, 8). FCMIA combines several classical methodologies: 
immunoassays, microspheres, and flow cytometry technology. In FCMIA, immunoassays 
are performed on sets of solid support microspheres with different characteristic internal 
fluorophores that allow multiple assays to be performed simultaneously (multiplexing). 
FCMIA has predominantly been used for multiple protein and nucleic acid analytes such as 
multiple antibodies in serum (9), multiple cytokines in serum (10), and multiple RNA and 
DNA viruses in patient samples (11). FCMIA assays are simple to set up and the instrument 
does not require an expert to operate.
Previously we developed an assay and sampling technique, capable of evaluating multiple 
drugs of abuse on surfaces using FCMIA (12), which has been used for exposure 
assessments in law enforcement evidence vaults (NIOSH HHEs 2012-0083-3189 and 
2010-0017-3133). We have also developed an easily performed technique to evaluate 
surface contamination by antineoplastic drugs in near real time (not yet published). 
Healthcare workers themselves, without the need of an anatlyical chemistry expert, can 
determine results within 15 minutes of sampling. In this report the feasibility of an FCMIA 
technique for surface sampling and detection of multple antineoplastic drugs is examined. 
Since there are no workplace standards for surface contamination by antineoplastic drugs, 
we aimed for detection of less than 1 ng/cm2 and measurement of less than 5 ng/cm2 of 
multiple antineoplastic drugs with a convenient and simple sampling technique. These levels 
will be useful in assessing contamination to control exposure. 5-fluorouracil, paclitaxel, and 
doxorubicin were chosen for study because these are commonly used drugs and reagents for 
FCMIA are available.
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Paclitaxel and doxorubicin standards were prepared by dissolving a weighed amount (about 
1 mg) of solid Paclitaxel (Sigma T7402, Sigma Aldrich, St Louis, MO) or solid doxorubicin 
(Sigma 44583-1 mg) in 1 ml methanol. The 5-fluorouracil standard was prepared by 
dissolving a weighed amount of 5-fluorouracil (Sigma F6627-1G) in concentrated 
ammonium hydroxide (product A669-500, Fisher Scientific, Fair Lawn, NJ). Fresh 5-
fluorouracil standard was prepared before each experiment.
5-flourouracil-bovine serum albumin (BSA), Doxorubicin-BSA, and Paclitaxel-BSA 
conjugates were purchased from Saladax Biomedical (Bethlehem, PA). These were 
produced by binding the drugs or drug analogs to the carrier protein (BSA). These 
conjugates are then tested for specific binding of anti-drug antibodies by the manufacturer. 
Monoclonal antibodies to 5-fluorouracil, paclitaxel and doxorubicin were obtained from 
Saladax or Lampire Biological Laboratories (Pipersville, PA). Microspheres were obtained 
from Luminex Corporation (Austin, TX). Activation buffer (0.1 M NaH2PO4, pH 6.2), 
coupling buffer (0.05 M 2-(N-morpholino) ethanesulfonic acid (MES), pH 5.0), wash buffer 
(phosphate buffered saline [PBS], 138 mM NaCl, 2.7 mM KCl, containing 0.05% Tween® 
20), storage/blocking buffer (PBS, 1% BSA, 0.05% NaN3, pH 7.4), were supplied or 
prepared with reagents supplied by Sigma Chemical Co. Biotin labeled anti-mouse IgG, 1-
ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide hydrochloride (EDC), and N-
hydroxysulfosuccinimide, sodium salt (sulfo-NHS) were obtained from Pierce 
Biotechnology, Inc. (Rockford, IL). StreptavidinR-phycoerythrin (streptavidin R-PE) was 
obtained from Molecular Probes (Eugene, OR).
Details concerning the multiplexed assay are given in a previous publication (12) so the 
assay will be briefly summarized here.
Microsphere preparation
Microspheres were 5.6 μm in diameter with surface carboxylate groups for covalent 
attachment of biomolecules. Internally, the microspheres were dyed with red and infrared 
emitting fluorochromes. By proportioning the concentrations of each fluorochrome, 
spectrally addressable microsphere sets were obtained. The carboxylate groups on the 
microspheres were activated with a mixture of EDC and NHS in activation buffer and the 
three drug-BSA conjugates in coupling buffer were coupled to separate unique sets of 
carboxylate-modified (Luminex) microspheres.
Multiplexed assay
The assay is a competitive assay, where drug in solution competes with a microsphere bound 
drug-BSA conjugate for an antidrug antibody. This results in less antidrug antibody being 
bound to the microsphere at higher drug concentrations. The antidrug antibody bound to the 
microsphere is detected with a labeled secondary antibody (biotin labeled anti-mouse IgG) 
which in turn binds a fluorescent label (streptavidin R-PE). Thus the streptavidin R-PE 
fluorescent signal from the microsphere decreases with increasing drug concentration. The 
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assay was performed in a 1.2 μm filter membrane microtiterplate (Millipore Corp., Part 
#MABVN1250, Bedford, MA) which allowed wash steps between the addition and 
incubation of primary antibody, secondary antibody, and streptavidin R-PE fluorescent 
label. After the steps of the assay were complete, the microtiterplate was placed in the 
autosampler platform of the LUMINEX 100 (Luminex) instrument for reading using 
software, calibration microspheres, and sheath fluid supplied by the manufacturer. The 
instrument was programmed to collect data from 100 microspheres for each analyte 
(classified by their internal fluorescence ratio) and acquire the median fluorescence intensity 
(MFI) of the microsphere-drug –BSA conjugate-primary anti-drug IgG antibody-secondary-
anti-IgG-biotin- streptavidin R-PE complex. The analysis of a sample containing 5-
fluorouracil, paclitaxel, and doxorubicin can be accomplished in less than 60 seconds using 
this system.
Mixtures of the three drugs were prepared at 8 concentrations shown in Table 1 in storage/
blocking buffer to measure the response of the assay. The range of concentrations of the 
standard solutions for each assay was determined by the known response of the assays.
Data Analyses
Standard curves were constructed from four-parameter logistic-log fits (4-PL, SigmaPlot, 
SPSS, Chicago, IL) of %B/Bo data (where B = the MFI for each individual drug standard 
and Bo = the MFI measured for the corresponding blank) versus ng/ml of standard. The 
limit of detection (LOD) of the assays was defined as 90% B/Bo and was interpolated 
mathematically from the coefficients of the 4-PL equations. Assessment of the “goodness of 
fit”and the dynamic ranges of the assays were investigated by evaluating the fit of the 
standards data to the 4-PL model by “standards recovery” (13), calculated by evaluating 
interpolated results from each 4-PL fit (observed concentration) and comparing them to the 
concentrations of drugs added to the system (the expected concentration) using the 
following relationship:
The resultant data were analyzed for linearity from the FCMIA LOD of each drug to highest 
the level studied by linear regression with the slope indicating recovery and the correlation 
coefficient giving goodness of fit.
To test for cross-reactivity among the drugs, increasing concentrations of the individual 
drugs were added to the mixture of 5-fluorouracil-BSA, paclitaxel-BSA, and doxorubicin-
BSA microspheres and anti-5-fluorouracil, anti- paclitaxel, anti- doxorubicin antibodies, and 
the assay was run as above. The cross-reactivity was determined by the response of each 
assay to analytes other than its own.
Recovery of Drugs from Surfaces
To study the recovery of drugs from surfaces, 10 cm × 10 cm square ceramic tiles (100 cm2 
area) with glazed nonporous surfaces were spiked with solutions of the drugs in methanol 
and the solution was allowed to dry to produce the desired surface loadings. The 
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concentrations of the spiking solutions was adjusted so that spiking the tiles with 50 μl 
would produce the desired surface loading. Three tiles were spiked at each level. The tiles 
were spiked with more than the individual assays’ upper limit which was adjusted according 
to the measured sampling efficiency. The surface loadings produced for the different drugs 
are shown in Table 2. The surface was then sampled using a swab (product no 71-7020, 
Super Brush LLC, Springfield, MA) wetted in wash buffer. The sampling was done by 
carefully wiping the surface with the wetted swab in one direction with an overlapping 
pattern, then repeating the same wiping pattern in a direction perpendicular to the first 
direction, and finally repeating the original wiping pattern. The swab was then placed in a 
glass vial containing 1 ml of storage/blocking buffer and the swab was extracted with 
vigorous shaking for 2 min. The resulting solution was run in the assay without any further 
dilution. The recovery was determined by comparing the concentration of the solution from 
wiped tile with the concentration calculated from the spiked masses of the drugs assuming 
100% recovery. The recovered mass was fitted to the spiked mass using least squares fit. 
The recovery from the surface was evaluated by the slope of the recovered mass curve. The 
lower limit of detection (LOD) was calculated as the spike mass equivalent to the blank (tile 
spiked with 0) + 3 times the standard deviation of the blank and the lower limit of 
quantitation (LOQ) was calculated as the spiked mass equivalent to the blank + 10 times the 
standard deviation of the blank using the recovered mass versus spiked mass relationship.
Results
Response Curves
Note that all data for the response curves are for the three drug analytes being measured 
simultaneously. The data shown are the average of 6 different runs for 5-fluorouracil and 
paclitaxel and 3 runs for the doxorubicin with the standard deviation shown as error bars. 
There were fewer runs for the doxorubicin because the range had to be changed since it is 
the most recently developed assay and was found to be not linear for the more extended 
range originally used. Due to the difference in the range for the assays, the following 
concentration ranges were used for standard curves: 5-fluorouracil 0–1000 ng/ml, paclitaxel 
0–100 ng/ml and doxorubicin 0–2 ng/ml.
5-fluorouracil—Figure 1 shows %B/Bo for 5-fluorouracil (B is the MFI at a given 
concentration and Bo is the MFI at 0 concentration) which shows a change from 100 %B/Bo 
to about 10 %B/Bo over the concentration range 0–1000 ng/ml. If 90% B/Bo is used as LOD 
then 13.4 ng/ml is the limit of detection. The curve was fitted with 4-PL function and the 
observed versus expected concentration is shown in Figure 1A which shows a good fit over 
the concentration range studied.
Paclitaxel—Figure 1 shows the %B/Bo curve for paclitaxel which shows 100 %B/Bo to 
about 5% over the concentration range of 0-100 ng/ml. The LOD based on 90% B/Bo is 1.6 
ng/ml. The correlation of observed concentration versus expected concentration based on the 
4-PL function is given in Figure 1B for concentration range 0-100 ng/ml.
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Doxorubicin—Figure 1 shows the %B/Bo curve for doxorubicin which shows 100% B/Bo 
to about 6% B/Bo over the range of 0–2 ng/ml. The LOD based on 90 %B/Bo is 0.019 
ng/ml. The observed concentration versus expected concentration correlations based on the 
4-PL function are given in Figure 1C for concentration range 0–1 ng/ml. Cross reactivity: As 
mentioned above, cross reactivity was evaluated by adding each drug singularly to the 
mixture of microspheres and antibodies for all three drugs. None of the assays showed 
significant change in %B/Bo to any analyte other than its own and therefore there was no 
significant cross reactivity between the analytes.
Recovery from Tiles
Again the tile recovery data is for the three drug analytes being measured simultaneously. 
The sensitivity of an assay based method for surface contamination will depend on the 
assay’s sensitivity and the efficiency of the sampling method. Therefore the tiles were 
spiked with more than the individual assays’ upper limit which was adjusted according to 
the measured sampling efficiency. Since the 5-fluorouracil method had a relatively higher 
sampling efficiency, the tiles were spiked with 2 times the assay range (0–1000 ng/ml) 
resulting in a spiking range of 0–2000 ng/tile. The paclitaxel had a relatively low sampling 
efficiency so the tiles were spiked with 10 times the assay range (0–100 ng/ml) resulting in a 
spiking range of 0–1000 ng/tile. Doxorubicin had an intermediate sampling efficiency so the 
tiles were spiked with 2.5 times the assay range (0–1 ng/ml) resulting in the spiking range of 
0–2.5 ng/tile. Note that the limits of detection and quantitation were calculated based on the 
average of all experiments.
Figure 2 shows the recovery curve for the 5-fluorouracil spiked tiles. It shows recovery that 
could be modeled as a line as a function of surface mass loading over the range of 0–2000 
ng/tile although the relative standard deviation was larger at the higher end and overall 
recovery was about 34%. The estimated LOD based on blank + 3 times standard deviation 
of blank was 93 ng/tile (0.93 ng/cm2) and the LOQ based on blank + 10 times standard 
deviation of blank was 280 ng/tile (2.8 ng/cm2).
Figure 3 shows the paclitaxel recovery over the range of 0–1000 ng/tile. The 0–1000 curve 
showed curvature at lower loading so the range of 0–62.5 ng/tile was also plotted. The 0–
1000 range shows low recovery (about 1.4 %) that can be modeled as a line over the upper 
range but the 0–62.5 range shows somewhat better recovery (about 2.8%). Even with the 
low recovery, the relative standard deviation is small over the entire 0–1000 range as shown 
by the small error bars. The better recovery at lower surface loading might be expected due 
to the low solubility of paclitaxel in buffer solution. The estimated LOD based on blank + 3 
times standard deviation of blank was 57 ng/tile (0.57 ng/cm2) and the LOQ based on blank 
+ 10 times standard deviation of blank was 206 ng/tile (2.06 ng/cm2) based on the 0–62.5 
ng/tile curve.
Figure 4 shows doxorubicin recovery (about 21%) over the range 0–2.5 ng/tile. The 
estimated LOD based on blank + 3 times standard deviation of blank was 0.36 ng/tile 
(0.0036 ng/cm2) and the LOQ based on blank + 10 times standard deviation of blank was 
1.3 ng/tile (0.013 ng/cm2) based on the 0–2.5 ng/tile curve.
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Contamination of workplace surfaces by antineoplastic drugs continues to be a problems 
since there is evidence that these drugs can produce exposure through skin contact (1, 14, 
15). Therefore methods to determine surface contamination are needed. The multidrug assay 
based on FCMIA was capable of detecting and measuring three antineoplastic drugs (5-
fluorouracil, paclitaxel, and doxorubicin) simultaneously with LODs less than 1 ng/cm2 
(100 ng/tile) and LOQs less than 5 ng/cm2 (500 ng/tile). The LOD for the 5-fluorouracil 
recovery was close to 1 ng/cm2 but it was calculated based on the average of all data for all 
runs and calculated LODs of individual runs were lower. The sampling technique is simple 
and the assay is capable of being done rapidly at relatively low cost once it is set up. The 5-
fluoruracil assay was relatively insensitive compared to the other assays. The same reagents 
were used in development of a lateral flow immunoassay which had a LOD of 5 ng/ml or 
less so it is not known why the FCMIA assay for 5-fluoruracil was less sensitive. The LOD 
of an LC-MS/MS based method for 5-fluorouracil was 0.06 ng/cm2 (6). The paclitaxel assay 
was more sensitive than the 5-fluorouracil assay but the wiping technique was considerably 
less effective at sampling the surface. Even with the low sampling efficiency the paclitaxel 
assay was able to detect less than 1 ng/cm2. The paclitaxel recovery curve may need to be 
divided into several regions to cover the entire range of 0–1000 ng/tile if semi-quantitative 
results are desired. In this study, the curve that included all data from 0–1000 ng/tile fit the 
data from 125 ng/tile to 1000 ng/tile while the curve that only included data from 0–62.5 ng/
tile fit the data in that range better than the overall curve. The paclitaxel sampling and 
analysis technique was also the most reproducible of all the assays as indicated by the small 
error bars. Ways of improving the recovery of paclitaxel could be studied but the modified 
procedure would have to be compatible with the immunoassay and be simple and 
convenient. The LOD of an LC-MS/MS based method for paclitaxel was 0.07 ng/cm2 (6) 
The doxorubicin assay is the most sensitive and it has intermediate recovery resulting in 
considerably lower LOD and LOQ for surface sampling than paclitaxel and 5-fluorouracil. 
The LOD of an LC-MS/MS based method for doxorubixcin was 0.20 ng/cm2 (6). In this 
study surface sampling was investigated for glazed ceramic surfaces only but we have 
performed another study that indicated that 5-fluorouracil recovery is similar but not 
identical from a range of surfaces such as vinyl tiles, stainless steel, glass and composite 
using a similar sampling method and analysis with both an immunochemical and LC-
MS/MS analysis method (data not shown). Further evaluation of this assay would include 
determining recovery from a range of surfaces in addition to ceramic tiles and other samples 
such as drug vials, gloves, and drug preparation mats.
The main use of this assay would be for screening surfaces in pharmacies, clinics, and drug 
manufacturing facilities for contamination by antineoplastic drugs. Of special interest are 
pharmacy areas such as hoods for drug preparation and nursing areas where drugs are 
administered to patients. Instrumental methods are more sensitive and specific than this 
assay for several of the drugs (e.g. 5-fluorouracil) but routine use of instrumental methods is 
expensive and samples have to be sent to a laboratory to perform the analysis which results 
in delays in obtaining results. Since this assay is simple, it could be set up to be performed at 
the worksite to provide more timely results. The components of the assay could be supplied 
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as a kit that someone with limited training could use. Use of this assay may provide a lower 
cost method for routine application.
It would be desirable to add more drugs to the FCMIA assay to screen for contamination for 
a wider arrays of drugs. This would require the development of antibodies and drug-protein 
conjugates for the additional drugs which is a limitation of the assay. Also cross reactivity 
between the drugs being measured as well as other drugs that might be present would have 
to be assessed. The addition of other drugs would result in minmal increases in the time to 
perform the assay and the FCMIA assay might be used for more drugs at a relatively low 
cost.
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%B/Bo for 5-fluorouracil, paclitaxel, and doxorubicin multiplex assays: B is the MFI assay 
signal at a given concentration and Bo is MFI assay signal at 0 concentration. Note that the 
range of 5-fluorouracil assay is 0–1000 ng/ml, the range for the paclitaxel assay is 0–100 
ng/ml, and the range for the doxorubicin assays is 0–2 ng/ml. Errors bars are standard 
deviation for multiple runs.
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Observed Concentration versus Expected Concentration for 5-fluorouracil assay: The 
response curve for 5-fluorouracil shown in Figure 1 was modeled with a 4 parameter logistic 
fit and the model was used to calculate observed concentration at each calibration point. 
This was plotted against expected concentration obtained from dilution factors.
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Observed Concentration versus Expected Concentration for paclitaxel assay: The response 
curve for paclitaxel shown in Figure 1 was modeled with a 4 parameter logistic fit and the 
model was used to calculate observed concentration at each calibration point. This was 
plotted against expected concentration obtained from dilution factors.
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Observed Concentration versus Expected Concentration for doxorubicin assay: The response 
curve for doxorubicin shown in Figure 1 was modeled with a 4 parameter logistic fit and the 
model was used to calculate observed concentration at each calibration point. This was 
plotted against expected concentration obtained from dilution factorsfor the 0–1 ng/ml 
range.
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5-fluorouracil recovery from spiked tiles: Tiles were spiked with 5-fluorouracil masses from 
0–2000 ng/tile, the tiles were sampled by wiping, and the recovered mass was determined by 
the 5-fluorouracil multiplex assay.
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Paclitaxel recovery from spiked tiles: Tiles were spiked with paclitaxel masses from 0–1000 
ng/tile, the tiles were sampled by wiping, and the recovered mass was determined by the 
paclitaxel multiplex assay. Data are plotted for both the 0–1000 ng/tile and 0–62.5 ng/tile 
ranges.
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Doxorubicin recovery from spiked tiles: Tiles were spiked with doxorubicin masses from 0–
2.5 ng/tile, the tiles were sampled by wiping, and the recovered mass was determined by the 
doxorubicin multiplex assay.
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Table 1
Concentration of Drugs in Standard Solutions
standard solution 5-fluorouracil (ng/ml) Paclitaxel (ng/ml) Doxorubicin (ng/ml)
1 1000 100 2
2 500 50 1
3 250 25 0.5
4 125 12.5 0.25
5 62.5 6.25 0.125
6 31.25 3.125 0.0625
7 15.6 1.5625 0.0312
8 0 0 0
The concentration 5-fluorouracil, paclitaxel, and doxorubicin in each standard solution used to determine the response of the assay.
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Table 2
Mass of Drugs on Tiles
Tile 5-fluorouracil (ng/tile) Paclitaxel (ng/tile) Doxorubicin (ng/tile)
1 2000 1000 5
2 1000 500 2.5
3 500 250 1.25
4 250 125 0.625
5 125 62.5 0.312
6 62.5 31.25 0.156
7 31.25 15.625 0.0781
8 0 0 0
The mass of 5-fluorouracil, paclitaxel, and doxorubicin on the tiles used to determine the recovery of the drugs from the surface.
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